Pages that link to "Q37103078"
Jump to navigation
Jump to search
The following pages link to Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group (Q37103078):
Displaying 50 items.
- Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma (Q24602657) (← links)
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity (Q26796313) (← links)
- Interleukin-7 and interleukin-15 for cancer (Q26830709) (← links)
- Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma (Q33408675) (← links)
- Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis (Q33409568) (← links)
- Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma (Q33597441) (← links)
- New aspects of neuroblastoma treatment: ASPHO 2011 symposium review (Q33922797) (← links)
- Monoclonal antibodies: versatile platforms for cancer immunotherapy (Q34111693) (← links)
- The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma (Q34186886) (← links)
- Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma (Q34205125) (← links)
- Anti-GD2 Strategy in the Treatment of Neuroblastoma (Q34243887) (← links)
- Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy (Q34389202) (← links)
- Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study (Q34488726) (← links)
- Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy (Q34541113) (← links)
- Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors (Q34589401) (← links)
- Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting (Q34683623) (← links)
- Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. (Q34877582) (← links)
- Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody (Q35077759) (← links)
- Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA (Q35381031) (← links)
- Neutrophils induced licensing of natural killer cells (Q35568172) (← links)
- Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. (Q35587509) (← links)
- Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor (Q35721147) (← links)
- Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid (Q35752673) (← links)
- Promising therapeutic targets in neuroblastoma (Q36055313) (← links)
- Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo (Q36057459) (← links)
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment (Q36455017) (← links)
- Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy (Q36564275) (← links)
- Dinutuximab and Panobinostat (Q36572408) (← links)
- Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastoma (Q36589638) (← links)
- RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY. (Q36776358) (← links)
- Immunology and immunotherapy of neuroblastoma (Q36856798) (← links)
- Current and Potential Uses of Immunocytokines as Cancer Immunotherapy (Q37637949) (← links)
- High-risk neuroblastoma: a therapy in evolution (Q37642871) (← links)
- Anti-GD2 antibody therapy for GD2-expressing tumors (Q37702283) (← links)
- p53 family: Therapeutic targets in neuroblastoma (Q37707387) (← links)
- Pharmacotherapy of neuroblastoma (Q37735199) (← links)
- Radioimmunotherapy of Solid Tumors: Searching for the Right Target (Q37804904) (← links)
- Treatment of high-risk neuroblastoma with anti-GD2 antibodies (Q37820755) (← links)
- Targeted therapy in pediatric and adolescent oncology (Q37869437) (← links)
- Development of treatment strategies for advanced neuroblastoma (Q38010377) (← links)
- Ten challenges in the management of neuroblastoma. (Q38029366) (← links)
- Glycans as targets for therapeutic antitumor antibodies (Q38034815) (← links)
- Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies (Q38079519) (← links)
- Emerging drugs for neuroblastoma (Q38108399) (← links)
- Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis (Q38352205) (← links)
- Targeted approaches to childhood cancer: progress in drug discovery and development (Q38404462) (← links)
- Dinutuximab: first global approval (Q38458853) (← links)
- Dinutuximab: A Review in High-Risk Neuroblastoma (Q38739672) (← links)
- Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma (Q38751090) (← links)
- Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma (Q38757939) (← links)